journal article·2025-12-19

Tumor Microenvironment-Mediated Activation of Oxidative Stress Storm for MRI-Guided Ferroptosis Therapy

Anfei Huang, Jiaming Lin, Yufeng Huang, Ming Gong, Lin Huang, Guo Fu, Jin Wang

ACS Applied Nano Materials· Volume 8· Issue 50
Publisher page

Abstract

Introduction: Ferroptosis therapy, despite its promise, encounters challenges such as compromised catalytic performance due to an inadequate H 2 O 2 substrate, the robust antioxidant defense system within the tumor microenvironment (TME), and potential off-target adverse events, leading to suboptimal efficacy. Methods: To overcome these limitations, we propose a strategy for TME-mediated activation of a potent oxidative stress storm to enhance MRI-guided multiple-amplified ferroptosis therapy for tumors. Results: The synthesized Fe-LAP@HMON-TAM-PEOz nanoparticles demonstrate precise and highly effective tumor-specific catalysis for antitumor therapy. This is achieved through an improved tumor accumulation strategy driven by charge-reversal-mediated active targeting and a multiple amplification approach for ferroptosis therapy, involving H 2 O 2 self-supplementation, GSH depletion, subsequent oxidative stress storm generation, and LPO accumulation, resulting in a robust antitumor response. Furthermore, the rapid degradation of nanoparticles in response to the H + /GSH stimulus within the TME facilitates the release of Mn 2+ from Fe-LAP@HMON-TAM-PEOz. This released Mn 2+ significantly enhances tumor brightness in T 1 -weighted MRI, characterized by a high r 1 value. Conclusion: Consequently, our synthesized Fe-LAP@HMON-TAM-PEOz nanoparticles exhibit excellent biodegradability and minimal side effects, highlighting their tremendous potential for highly efficient tumor theranostics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Ferroptosis and cancer prognosis · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Musculoskeletal Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer

Sun Yat-sen University Cancer Center

Department of VIP Region, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer

Department of Cervical Spondylosis and Spine Orthopedics

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangdong Clinical Research Academy of Chinese Medicine

Department of Pediatric Orthopedics, Guangzhou Women and Children’s Medical Center, No. 9 Jinsui Road, Guangzhou, Guangdong 510623, China

School of Biomedical Engineering, Southern Medical University, 1023 Shatai South Road, Guangzhou, Guangdong 510515, China

Department of Orthopedic Trauma and Foot and Ankle

Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Funding

National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.1021/jacs.6b1184610.1021/jacs.6b11846 ↗
2. 10.1073/pnas.15266739910.1073/pnas.152667399 ↗
3. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
4. 10.1038/s41556-020-0461-810.1038/s41556-020-0461-8 ↗
5. 10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
6. 10.1126/sciadv.aax093710.1126/sciadv.aax0937 ↗
7. 10.1021/acsnano.3c0463210.1021/acsnano.3c04632 ↗
8. 10.1002/anie.20221744810.1002/anie.202217448 ↗
9. 10.1126/scitranslmed.adg304910.1126/scitranslmed.adg3049 ↗
10. 10.1016/j.bbrc.2021.06.05110.1016/j.bbrc.2021.06.051 ↗
11. 10.1038/s41586-021-03539-710.1038/s41586-021-03539-7 ↗
12. 10.1038/s41401-020-0478-310.1038/s41401-020-0478-3 ↗
13. 10.1016/j.actbio.2021.09.00310.1016/j.actbio.2021.09.003 ↗
14. 10.1039/D2BM01172G10.1039/D2BM01172G ↗
15. 10.1016/j.cclet.2025.11169210.1016/j.cclet.2025.111692 ↗
16. 10.1039/D3CS00001J10.1039/D3CS00001J ↗
17. 10.1186/s12951-024-02457-w10.1186/s12951-024-02457-w ↗
18. 10.1007/s11095-014-1436-x10.1007/s11095-014-1436-x ↗
19. 10.1002/jmri.2859010.1002/jmri.28590 ↗
20. 10.1021/ja508721y10.1021/ja508721y ↗
21. 10.1021/acsnano.8b0605810.1021/acsnano.8b06058 ↗
22. 10.1016/j.jcis.2024.01.03410.1016/j.jcis.2024.01.034 ↗
23. 10.1016/j.cej.2022.14086810.1016/j.cej.2022.140868 ↗
24. 10.1002/adfm.20201039010.1002/adfm.202010390 ↗
25. 10.1002/adfm.20190771610.1002/adfm.201907716 ↗
26. 10.1021/acsnano.7b0810310.1021/acsnano.7b08103 ↗
27. 10.1016/j.nantod.2023.10193110.1016/j.nantod.2023.101931 ↗
28. 10.2147/IJN.S9340910.2147/IJN.S93409 ↗
29. Sachdev, J.; Ramanathan, R.; Raghunand, N.; Kim, J.; Klinz, S.; Bayever, E.; Fitzgerald, J.; Korn, R. Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI) Cancer Res 2015; Vol. 75 9_Supplement.10.1158/1538-7445.SABCS14-P5-01-06 ↗
30. 10.1002/adma.20170037310.1002/adma.201700373 ↗
31. 10.1002/adfm.20220927810.1002/adfm.202209278 ↗
32. 10.1021/acs.nanolett.1c0313010.1021/acs.nanolett.1c03130 ↗
33. 10.1002/adhm.20220336210.1002/adhm.202203362 ↗
34. 10.1016/j.jconrel.2021.09.00510.1016/j.jconrel.2021.09.005 ↗
35. 10.1016/j.biomaterials.2021.12100110.1016/j.biomaterials.2021.121001 ↗
36. 10.1002/smll.20210463210.1002/smll.202104632 ↗
37. 10.1039/C9SC06260B10.1039/C9SC06260B ↗
38. 10.1021/acsnano.3c0136910.1021/acsnano.3c01369 ↗
39. 10.3389/fphar.2019.0027010.3389/fphar.2019.00270 ↗
40. 10.1021/acsami.9b0305610.1021/acsami.9b03056 ↗
41. 10.1021/acsami.1c2243210.1021/acsami.1c22432 ↗
42. 10.1021/acsami.9b0932310.1021/acsami.9b09323 ↗
43. 10.1021/acsnano.0c0076410.1021/acsnano.0c00764 ↗
44. 10.1002/smll.20200218810.1002/smll.202002188 ↗
45. 10.1016/j.chempr.2022.03.00910.1016/j.chempr.2022.03.009 ↗
46. 10.1039/D1CC06742G10.1039/D1CC06742G ↗
47. 10.1021/acsnano.2c0096910.1021/acsnano.2c00969 ↗
48. 10.1002/adfm.20200807810.1002/adfm.202008078 ↗